Johnson & Johnson
Johnson & Johnson (JNJ) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · JNJ · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
21
12 Months
Buy/Sell ratio
0.05
Buy/Sell (by trades)
Overall sentiment
Johnson & Johnson insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
JNJ insider buying and selling by quarter
JNJ insider selling · JNJ insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · JNJ ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
JNJ executive sell shares · JNJ board member insider trading · JNJ insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 1, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Option | 25,255 | — | Form 4 |
| May 1, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Other | 11,002 | $2.53M⚡ | Form 4 |
| Feb 27, 2026 | Decker Robert J VP Corporate Controller | Option | 4,075 | $471K | Form 4 |
| Feb 27, 2026 | Decker Robert J VP Corporate Controller | Sale | 4,075 | $1.01M⚡ | Form 4 |
| Feb 20, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Sale | 1,322 | $325K | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Option | 22,191 | $3.61M⚡ | Form 4 |
| Feb 17, 2026 | Swanson James D. EVP, CIO | Option | 20,521 | $3.38M⚡ | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Option | 19,368 | $3.21M⚡ | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Option | 9,412 | — | Form 4 |
| Feb 15, 2026 | Swanson James D. EVP, CIO | Option | 709 | — | Form 4 |
| Feb 17, 2026 | Swanson James D. EVP, CIO | Sale | 20,521 | $4.98M⚡ | Form 4 |
| Feb 15, 2026 | Swanson James D. EVP, CIO | Other | 309 | $75K | Form 4 |
| Feb 15, 2026 | Swanson James D. EVP, CIO | Option | 492 | — | Form 4 |
| Feb 15, 2026 | Swanson James D. EVP, CIO | Other | 214 | $52K | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Sale | 22,191 | $5.41M⚡ | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Other | 3,547 | $867K | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Sale | 19,368 | $4.72M⚡ | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Option | 447 | — | Form 4 |
| Feb 13, 2026 | Swanson James D. EVP, CIO | Other | 143 | $35K | Form 4 |
| Feb 13, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Option | 13,706 | — | Form 4 |
| Feb 15, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Option | 635 | — | Form 4 |
| Feb 15, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Other | 325 | $79K | Form 4 |
| Feb 15, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Option | 606 | — | Form 4 |
| Feb 15, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Other | 310 | $75K | Form 4 |
| Feb 13, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Other | 6,414 | $1.57M⚡ | Form 4 |
REED JOHN C
EVP, Innovative Medicine, R&D
Date
May 1
Shares
25,255
Price
—
Value
—
REED JOHN C
EVP, Innovative Medicine, R&D
Date
May 1
Shares
11,002
Price
$229.85
Value
$2.53M ⚡
Decker Robert J
VP Corporate Controller
Date
Feb 27
Shares
4,075
Price
$115.67
Value
$471K
Decker Robert J
VP Corporate Controller
Date
Feb 27
Shares
4,075
Price
$247.87
Value
$1.01M ⚡
Schmid Timothy
EVP, WW Chair, MedTech
Date
Feb 20
Shares
1,322
Price
$245.66
Value
$325K
Wengel Kathryn E
EVP, Chief TO and Risk Officer
Date
Feb 13
Shares
13,706
Price
—
Value
—
Wengel Kathryn E
EVP, Chief TO and Risk Officer
Date
Feb 15
Shares
635
Price
—
Value
—
Wengel Kathryn E
EVP, Chief TO and Risk Officer
Date
Feb 15
Shares
325
Price
$243.45
Value
$79K
Wengel Kathryn E
EVP, Chief TO and Risk Officer
Date
Feb 15
Shares
606
Price
—
Value
—
Wengel Kathryn E
EVP, Chief TO and Risk Officer
Date
Feb 15
Shares
310
Price
$243.45
Value
$75K
Wengel Kathryn E
EVP, Chief TO and Risk Officer
Date
Feb 13
Shares
6,414
Price
$244.55
Value
$1.57M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About JNJ insider trading
JNJ insider trades
Johnson & Johnson (JNJ) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Wolk Joseph J (Exec VP, CFO), Swanson James D. (EVP, CIO), Wengel Kathryn E (EVP, Chief TO and Risk Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. JNJ insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Johnson & Johnson's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
JNJ insider trading · 5 questionsThe insiders of Johnson & Johnson (JNJ) include executives and directors such as Wolk Joseph J (Exec VP, CFO), Swanson James D. (EVP, CIO), Wengel Kathryn E (EVP, Chief TO and Risk Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026